Gennex Laboratories Limited (GENNEX.BO)
- Previous Close
13.11 - Open
13.22 - Bid 13.07 x --
- Ask 13.15 x --
- Day's Range
12.90 - 13.45 - 52 Week Range
11.15 - 19.00 - Volume
316,989 - Avg. Volume
938,231 - Market Cap (intraday)
2.973B - Beta (5Y Monthly) 0.66
- PE Ratio (TTM)
16.76 - EPS (TTM)
0.78 - Earnings Date May 28, 2025 - Jun 2, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date Sep 10, 2001
- 1y Target Est
--
Gennex Laboratories Limited engages in manufacturing and selling of bulk drugs, intermediates, and biotech products. The company offers Guaifenesin, Methocarbamol, Fexifenadine Hcl, Phenazopyridine Hcl, Fluconazole, Melitracen Hcl, Mephenesin, Chlorphenesin, Sertraline Hcl, and Allopurinol. It operates in India, Colombia, Egypt, Germany, Iran, Peru, Saudi Arabia, Spain, Thailand, and Vietnam. The company was formerly known as Prudential Pharmaceuticals Limited. Gennex Laboratories Limited was incorporated in 1990 and is based in Hyderabad, India.
www.gennexlab.com129
Full Time Employees
March 31
Fiscal Year Ends
Sector
Recent News: GENNEX.BO
View MorePerformance Overview: GENNEX.BO
Trailing total returns as of 5/23/2025, which may include dividends or other distributions. Benchmark is S&P BSE SENSEX (^BSESN) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: GENNEX.BO
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: GENNEX.BO
View MoreValuation Measures
Market Cap
2.98B
Enterprise Value
2.75B
Trailing P/E
16.83
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
2.64
Price/Book (mrq)
1.65
Enterprise Value/Revenue
2.23
Enterprise Value/EBITDA
9.97
Financial Highlights
Profitability and Income Statement
Profit Margin
14.38%
Return on Assets (ttm)
--
Return on Equity (ttm)
--
Revenue (ttm)
1.31B
Net Income Avi to Common (ttm)
188.46M
Diluted EPS (ttm)
0.78
Balance Sheet and Cash Flow
Total Cash (mrq)
525.37M
Total Debt/Equity (mrq)
15.73%
Levered Free Cash Flow (ttm)
--